Consumer Brands · NYSE: CL
Colgate-Palmolive earnings: results, call transcripts & KPI history
2 quarters · fiscal year ends December · next results expected around 29 Jan 2027
Latest: Q3 2026
Colgate is racing to rebuild its U.S. business around premium innovation and AI-driven marketing while emerging markets and Hill's pet nutrition carry global growth.
Growth was broad-based: organic sales rose in all four categories and four of five divisions. Emerging markets led, with India, Brazil and China cited as drivers. Hill's pet nutrition had a strong quarter, helped by therapeutic diets, cat and wet food, and the late-June launch of single-protein fresh diets. Toothpaste, toothbrush and mouthwash shares rose in several markets. North America remained the weak spot.
Quarters
KPI history
Fourth quarter worked out from the annual figure.
Data
| Q4 2024 | $4.9B * |
| Q1 2025 | $4.9B |
| Q2 2025 | $5.1B |
| Q3 2025 | $5.1B |
| Q4 2025 | $5.2B * |
| Q1 2026 | $5.3B |
| Q2 2026 | $5.4B |
| Q3 2026 | $5.4B |
Data
| Q1 2025 | $0.85 |
| Q2 2025 | $0.91 |
| Q3 2025 | $0.91 |
| Q1 2026 | $0.80 |
| Q2 2026 | $0.86 |
| Q3 2026 | $0.94 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 2024 | 21.5% |
| Q1 2025 | 21.9% |
| Q2 2025 | 21.1% |
| Q3 2025 | 20.6% |
| Q4 2025 | 1.8% |
| Q1 2026 | 18.1% |
| Q2 2026 | 19.0% |
| Q3 2026 | 20.3% |
Data
| Q4 2024 | $1.1B |
| Q1 2025 | $476.0M |
| Q2 2025 | $776.0M |
| Q3 2025 | $1.1B |
| Q4 2025 | $1.3B |
| Q1 2026 | $609.0M |
| Q2 2026 | $867.0M |
| Q3 2026 | $1.0B |
Operating cash flow minus capital expenditure, from cash flow statements.
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.9Bd | $4.9B | $5.1B | $5.1B | $5.2Bd | $5.3B | $5.4B | $5.4B |
| Gross margin | 60.3% | 60.8% | 60.1% | 59.4% | 60.2% | 60.6% | 61.5% | 60.2% |
| Operating income | $1.1Bd | $1.1B | $1.1B | $1.1B | $92.0Md | $964.0M | $1.0B | $1.1B |
| Operating margin | 21.5% | 21.9% | 21.1% | 20.6% | 1.8% | 18.1% | 19.0% | 20.3% |
| Net income | $739.0Md | $690.0M | $743.0M | $735.0M | -$37.0Md | $646.0M | $693.0M | $751.0M |
| Diluted EPS | — | $0.85 | $0.91 | $0.91 | — | $0.80 | $0.86 | $0.94 |
| Operating cash flow | $1.3Bd | $600.0M | $884.0Md | $1.3Bd | $1.5Bd | $747.0M | $995.0Md | $1.2Bd |
| Capital expenditure | $184.0Md | $124.0M | $108.0Md | $155.0Md | $177.0Md | $138.0M | $128.0Md | $134.0Md |
| Free cash flow | $1.1B | $476.0M | $776.0M | $1.1B | $1.3B | $609.0M | $867.0M | $1.0B |
From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.
10-K and 10-Q filings
- 30 Oct 202610-Q for the period ended 30 Sep 2026SEC ↗
- 31 Jul 202610-Q for the period ended 30 Jun 2026SEC ↗
- 1 May 202610-Q for the period ended 31 Mar 2026SEC ↗
- 23 Feb 202610-K for the period ended 31 Dec 2025SEC ↗
- 31 Oct 202510-Q for the period ended 30 Sep 2025SEC ↗
- 1 Aug 202510-Q for the period ended 30 Jun 2025SEC ↗
- 25 Apr 202510-Q for the period ended 31 Mar 2025SEC ↗
- 13 Feb 202510-K for the period ended 31 Dec 2024SEC ↗